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See Article, pages 515–522Patients who recover from acute hepatitis B clear surface antigen
(HBsAg) from serum and anti-HBs becomes detectable as hall-
mark of HBV immune control. However, anti-HBs appear weeks
after HBsAg clearance and neutralizing antibodies are unlikely
to contribute to early viral control but to prevent viral spread
from cells that remain infected after hepatitis resolution [1]. This
notion is supported by the evidence that chimpanzees resolving
hepatitis B are protected from viral rechallenge [2]. Similarly, in
non-infected individuals an adequate anti-HBs production
(>10 mUI/ml) indicates a protective immunity after vaccination
[1]. Several evidences suggest that anti-HBs are present also in
chronic HBsAg carriers, but not detected because hidden in circu-
lating immune-complexes [3]. Thus the simultaneous detection
of HBsAg/anti-HBs (HBsAg/anti-HBs-co-detection) represents an
atypical serologic proﬁle puzzling virologists and clinicians since
the late 1970s [3–5]. Initially, it was explained by heterologous
antibodies against subtypes different from the infecting HBV sub-
type, as HBsAg subtypes d/y infections could associate with y/d
anti-HBs subtypes [6]. The hypothesis of primary infection with
2 subtypes followed by clearance of only one of them was con-
tradicted by the animal model where humoral response against
the a determinant of HBsAg prevented the re-infection with dif-
ferent HBV subtypes [3]. In addition, ay anti-HBs was found in
HBsAg carriers from Japan, where this subtype is uncommon
[7]. Therefore, the hypothesis of a mixed infection was dismissed
in favour of clonal selection of antibody diversity [3]. The high
similarity between 2 HBV serotypes (i.e., HBsAg/ad and HBsAg/
ay) could induce the clonal expansion not only of high-titre,
high-afﬁnity anti-a and anti-d, but also lower-titre, low-afﬁnity
heterotypic anti-y [3,4]. Nevertheless, the question remains
why only a minority of HBsAg carriers exhibit this condition.
After the introduction of molecular biology techniques the
characterization of viral quasispecies in clinical settings of HBV
infections despite vaccination or HBIg treatment showed that
HBsAg/anti-HBs-co-detection was associated with viral strains
carrying HBsAg mutations that escaped the anti-HBs neutraliza-
tion [8,9]. These ﬁndings raise the question whether geneticJournal of Hepatology 20
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Open access under CC BY-NC-ND license.heterogeneity of HBV and particularly of the S gene could also
be present in other HBsAg/anti-HBs carriers.
Serum HBsAg results from one open reading frame providing
3 carboxy-terminal collinear proteins of different length (small,
medium, and large, SHBs, MHBs, LHBs). In addition to the S gene
MHBs contains pre-S2 sequence (55 aa) and LHBs preS1 (108/119
aa depending on subtype) and preS2 sequences. PreS1 and PreS2
and the aa 100–169 domain of SHBs (Major Hydrophilic Region,
MHR) are exposed on viral particles and highly immunogenic.
The studies of HBsAg variants focused mainly on SHBs, because
it is expressed at the highest levels, predominates in both virions
and subviral particles and contains within MHR the ‘‘a’’ determi-
nant (aa 124–147), main target of neutralizing antibodies. Two
major loops are present in the ‘‘a’’ determinant (the 1st at aa
124–137; the 2nd at aa 139–147), deﬁned by multiple potential
disulﬁde bridges, between aa 139/147 (or 149) and 121/124;
conserved cysteines at 124, 137, 139, and 149 are essential for
conformation and antigenicity [9]. MHR is the principal
anti-HBs binding site after natural infection, immunisation and
HBIg prophylaxis, although areas up and downstream may also
be important in neutralisation. Initially characterized vaccine
and HBIg escape mutants showed glycine to arginine substitu-
tions at position 145 (G145R); later other mutations between
120 and 208 were described in patients with active or passive
immune-prophylaxis or CHB [10].
Overall, in both Western and Asian cohorts a signiﬁcantly
higher S gene variability, particularly of MHR with higher number
of aa substitutions was found in HBsAg/anti-HBs positive patients
than in controls [11–16]. Two French studies showed in the same
patients a signiﬁcantly higher number of aa changes in the ‘‘s’’
gene (aa substitution/100 aa: 4.55 vs. 1.66), even more evident
in MHR (5.71–4.68 vs. 1.43–2.07) and ‘‘a’’ determinant (9.52–
11.00 vs. 2.43–2.48). Aa substitutions were signiﬁcantly more fre-
quent at positions 120, 126, 129, 130, 144, and 165; G145R/T was
the most frequent [11,12]. These ﬁndings suggested that emer-
gence of ‘‘a’’ determinant variants could favour viral escape from
immune neutralization. Most of Asian studies conﬁrmed the
European ﬁndings except for a higher prevalence of aa changes
in the 1st loop (aa 124–137) of ‘‘a’’ determinant than in the
2nd (aa 137–145) [13–15]. When HBV genotype C infected
individuals were analysed the classic G145R substitution was
signiﬁcantly less frequent, with prevalent mutations at aa 126,14 vol. 60 j 473–475
Table 1. Biological and clinical implications of HBsAg/anti-HBs-co-detection.
HBsAg carrier Physio-pathologic mechanism Possible clinical implication
Immunocompetent Genetic heterogeneity of HBV replication leads to 
mutations in the S gene prompting the selection of 
under the pressure of the 
host’s immune response 
The long lasting immune clearance phase favours the 
selection of highly variable viral quasispecies not only 
in the S gene, but also in regions of the genome with 
relevant oncogenic potential that may increase the risk 
of HCC 
Immunocompromised Viral strains carrying HBsAg mutations may escape 
the neutralizing capacity of anti-HBs and eventually in 
very rare cases infect either vaccinated or HBIg treated 
individuals 
Individuals harbouring highly replicative HBV 
strains with mutations in the “a” determinant of the 
S gene are risky reservoir for spreading of HBV 
immunosuppression
variants with better fitness
infection, particularly in the specific clinical setting of
Editorial129, 130, 131, 133, and 134, conﬁrming a major inﬂuence of
genotype on selection of viral quasispecies [13–15]. However, a
potential role of immune suppression and antiviral therapy in
European patients cannot be ruled out. Interestingly, some stud-
ies showed a signiﬁcant variability of S gene at its CTL epitope (aa
87–95) that might contribute to HBV neutralization failure [13].
The major mechanism hypothesised for HBsAg/anti-HBs-co-
detection remained the change in primary sequence of ‘‘a’’ deter-
minant that alters its antigenic structure making the anti-HBs
response less effective. Nevertheless, the real impact of many
mutations on HBsAg antigenicity has yet to be determined. Yu
D-M et al. addressed this issue investigating the biological fea-
tures of 3 MHR mutants, identiﬁed among 216 Chinese HBsAg/
Anti-HBs carriers [16]. Authors conﬁrmed a signiﬁcantly higher
heterogeneity of ‘‘s’’ gene in HBsAg/anti-HBs patients as com-
pared to 182 controls, particularly within MHR (mutation preva-
lence 43.1% vs. 15.5%). Interestingly, 22% (47 of 216) of HBsAg/
Anti-HBs carriers harbored new N-glycosylation sites in the
MHR as compared to only 1 of 182 (0.5%) controls. The 8 potential
N-glycosylation sites were all located within or before the 1st
loop of HBsAg (aa substitutions 113, 114, 116, 123, 129, 130,
131, with an additional ‘‘N-X-T/S’’ motif by insertion between
114 and 115). They conﬁrmed clustered mutations in 129, 130,
and 131 and selected mutations in 129 and 131, together with
the 3 aa insertions functionally studied. They showed ﬁrstly by
PNGaseF treatment and site direct mutagenesis, that these muta-
tions produced new N-Glycosylation sites, then by deglycosyla-
tion experiments that the anti-HBs binding capacity of the 3
mutated proteins was several times lower. Finally, trans-comple-
mentation experiments with replication competent/secretion
defective HBV plasmid and mutated HBV-env constructs showed
an increase secretion of virions. These ﬁndings contribute to a
better understanding of the underlying biological mechanisms
of HBsAg/anti-HBs-co-detection and conﬁrm a major role of the
interplay between virus and immune system. On the one hand
the HBV replication pathway leads to mutations in the S gene
prompting the selection of variants with better ﬁtness once the
speciﬁc immune response has developed [16]. On the other hand
when both HBsAg and anti-HBs are detected in highly viremic,
HBeAg positive, immune tolerant carriers the alternative possibil-
ity that the heterogeneity of the antibodies production could
overcome the variability of the virus still holds true, as suggested
by Zhang et al. [17]. However, this is a classical chicken and egg
question since a single nucleotide change is enough to induce
aa substitutions at position 120, 126, and 160 shifting subtype
d to y, i to t and w to r [5].
In addition, Yu D-M et al. demonstrate the infectivity of the
129 mutant in one responder to HBV vaccine suggesting that474 Journal of Hepatology 201individuals harbouring these mutated HBV strains could repre-
sent a risky reservoir for the spread of HBV infection, even in
vaccinated individuals [16]. However, such an event appears
to occur only in speciﬁc clinical settings such as immune-com-
promised individuals who deserve a special attention and
careful monitoring. Another case was a HBsAg/HBeAg positive
immune tolerant patient, with initially undetectable anti-HBs,
who turned positive at the time of transition to immune
elimination phase, when the 131 mutant became detectable.
According to Authors the mutant was horizontally transmitted
at that time, but, alternatively, we may speculate that the
variant was selected and emerged when the speciﬁc adaptive
anti-HBV immune response was mounted [16]. This ﬁnding
further supports the view that immune selection plays a pivotal
role and suggests that the prevalence of HBsAg/anti-HBs-
co-detection should increase in CHB patients. Actually, its
reported prevalence is extremely variable, ranging from 2.5%
to over 30% [5,11–17]; the changes of diagnostic criteria over-
time could explain at least in part such variability, but patient
heterogeneity seems a major cause. Accordingly, the HBsAg/
anti-HBs prevalence is lower (2.5–5%) in HBsAg carriers
identiﬁed by population screening, but increases up to 30% in
CHB patients. Shields et al. showed that 63% of CHB patients
were HBsAg/anti-HBs positive as compared to 14% of asymp-
tomatic carriers [18]. Furthermore, liver disease was shown to
progress more frequently to HCC in Korean HBsAg/anti-HBs
positive CHB patients who had also a higher prevalence of
pre-S mutations (42.4% vs. 20.4%) [19,20]. Yu et al. found a
higher prevalence of N-glycosylation mutation in HCC patients
as compared to controls (53% vs. 0%, p <0.001). Overall these
ﬁndings suggest that HBsAg/anti-HBs-co-detection is linked to
a long lasting immune clearance phase that favours the
selection of highly variable viral quasispecies not only in the S
gene, but also in regions of the genome with relevant oncogenic
potential.
In conclusion the possible clinical implications of HBsAg/
anti-HBs-co-detection are different according to the immune
competence of the chronic HBsAg carrier as indicated in Table 1.
However, not all studies conﬁrm the correlation between HBsAg/
anti-HBs-co-detection and severity of liver disease, thus its
clinical signiﬁcance remains to be better characterized in larger
prospective cohort studies.Conﬂict of interest
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